NASDAQ:VVOS

Vivos Therapeutics (VVOS) Stock Price, News & Analysis

Vivos Therapeutics logo
$0.06 -0.02 (-25.13%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$0.05 0.00 (-6.15%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Vivos Therapeutics Stock (NASDAQ:VVOS)

Advanced

Key Stats

Today's Range
$0.05
▼
$0.07
50-Day Range
$0.06
▼
$0.18
52-Week Range
$0.05
▼
$2.69
Volume
4.43 million shs
Average Volume
1.08 million shs
Market Capitalization
$1.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.80
Consensus Rating
Hold

Company Overview

Vivos Therapeutics is a medical technology company focused on treatments for sleep-disordered breathing, including obstructive sleep apnea. The company works with dental providers to offer non-surgical approaches intended to improve patients’ airways and breathing during sleep.

Its Vivos System combines proprietary oral appliances with treatment protocols used by trained dental professionals. The company also provides education and support to providers who offer its therapies.

Based in Littleton, Colorado, Vivos primarily serves patients through a network of participating dental practices. Its approach is designed for use in dental settings and may involve collaboration with other healthcare professionals.

AI Generated. May Contain Errors.

Vivos Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

VVOS MarketRank™: 
2.25196091922 of 5 stars

Vivos Therapeutics scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vivos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Vivos Therapeutics has a consensus price target of $2.80, representing about 4,820.9% upside from its current price of $0.06.

  • Amount of Analyst Coverage

    Vivos Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Vivos Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Vivos Therapeutics are expected to grow in the coming year, from ($1.30) to ($0.10) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vivos Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vivos Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    15.47% of the float of Vivos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vivos Therapeutics has a short interest ratio ("days to cover") of 0.25, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vivos Therapeutics has recently increased by 30.10%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Vivos Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Vivos Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Vivos Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Vivos Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for VVOS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Vivos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.40% of the stock of Vivos Therapeutics is held by insiders.

  • Percentage Held by Institutions

    26.35% of the stock of Vivos Therapeutics is held by institutions.

  • Read more about Vivos Therapeutics' insider trading history.
Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VVOS Stock News Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
See More Headlines

VVOS Stock Analysis - Frequently Asked Questions

Vivos Therapeutics' stock was trading at $2.03 at the beginning of 2026. Since then, VVOS stock has decreased by 97.2% and is now trading at $0.0569.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its quarterly earnings data on Monday, November, 16th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.23. The firm earned $6.41 million during the quarter, compared to the consensus estimate of $5.48 million. Vivos Therapeutics had a negative net margin of 107.36% and a negative trailing twelve-month return on equity of 2,325.64%.
Read the conference call transcript
.

Shares of Vivos Therapeutics reverse split on Friday, October 27th 2023.The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Vivos Therapeutics (VVOS) raised $21 million in an IPO on Thursday, December 10th 2020. The company issued 3,500,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Advanced Micro Devices (AMD), SoFi Technologies (SOFI), Tesla (TSLA), Alibaba Group (BABA), BigBear.ai (BBAI), Chevron (CVX) and Johnson & Johnson (JNJ).

Company Calendar

Last Earnings
11/16/2026
Today
11/20/2026
AGM 2026
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:VVOS
CIK
1716166
Fax
N/A
Employees
268
Year Founded
2013

Price Target and Rating

High Price Target
$3.10
Low Price Target
$2.50
Potential Upside/Downside
+4,820.9%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.48)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.17 million
Net Margins
-107.36%
Pretax Margin
-108.11%
Return on Equity
-2,325.64%
Return on Assets
-90.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.22
Quick Ratio
0.21

Sales & Book Value

Annual Sales
$17.44 million
Price / Sales
0.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
-0.81

Miscellaneous

Outstanding Shares
20,120,000
Free Float
19,836,000
Market Cap
$1.14 million
Optionable
Optionable
Beta
6.37

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:VVOS) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners